Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

Alzheimer's Disease Research - Current Award

Dr. Gal Bitan

Gal Bitan, Ph.D.

University of California, Los Angeles
Los Angeles, CA

Title: Rational design of amyloid beta-protein aggregation and toxicity inhibitors
Non-Technical Title: Rational design of novel drugs for Alzheimer's disease

Duration: April 1, 2008 - March 31, 2010
Award Type: Pilot
Award Amount: $100,000


Summary:

In this project we will use a novel approach that combines our most current understanding of the molecular processes that lead to AD. We do that by "tailoring" sophisticated weapons that target what is believed to be the very first event along the pathway that leads to formation of the toxic molecules that rob AD patients of their memory and personality.

Details:

Alzheimer's disease (AD) is a current major public health threat, which despite tremendous research efforts, to date has no cure. To cure and prevent the disease we must invent drugs that treat the root of the problem. In this project we will use a novel approach that combines our most current understanding of the molecular processes that lead to AD. We do that by "tailoring" sophisticated weapons that target what is believed to be the very first event along the pathway that leads to formation of the toxic molecules that rob AD patients of their memory and personality. Unlike the direction used by most pharmaceutical companies - screening of large, random collections of molecules,our study is the first example of using a rational-design approach that is based on the three-dimensional structure of the toxic protein that causes AD.